provider and patient on a case-by-case basis. In clinical trials, severe psoriasis has been defined as a Psoriasis Area and Severity Index (PASI) score ( 25 (Table 4 6 Treat-to-target (Table 5). This recommendation for patients with active PsA is conditional based on low-quality evidence. In patients with active PsA, using a treat-to-target strategy is recommended over not following a-treat-to-target strategy. One may consider not using a treat-to-target strategy in patients in whom there are